Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01802775 · ClinicalTrials.gov registry record · Phase 2

Edoxaban in Peripheral Arterial Disease

A Phase 2 study of Peripheral Arterial Disease, sponsored by Daiichi Sankyo.

Completed
Registry status
Phase 2
Development phase
203
Enrollment target
20
Study locations

NCT01802775 is a Phase 2 study of Peripheral Arterial Disease that has completed, run by Daiichi Sankyo. The registered enrollment target is 203 participants, below the 4,204-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01802775, a Phase 2 study of Peripheral Arterial Disease, has completed, sponsored by Daiichi Sankyo.

COMPLETED
Registry status
Phase 2
Development phase
203 participants
Enrollment target
20
Study locations

Study Summary

This study is a randomized, open-label, blinded endpoint, parallel-group, active-control, multi-center, proof-of-concept study in subjects with Peripheral Arterial Disease (PAD), designed to assess the safety and potential efficacy of adding edoxaban to aspirin following femoropopliteal endovascular intervention, with or without stent placement, relative to current treatment practice with clopidogrel and aspirin.

Conditions Studied

Peripheral Arterial Disease

Interventions

  • DRUG Aspirin
  • DRUG Clopidogrel
  • DRUG edoxaban

Study Locations (20)

California

  • - Beverly Hills
  • - Los Angeles
  • - Orange

Florida

  • - Hollywood
  • - Jacksonville

Michigan

  • - Flint
  • - Ypsilanti

North Carolina

  • - Raleigh
  • - Wilmington

Alabama

  • - Birmingham

Arizona

  • - Phoenix

Connecticut

  • - New Haven

Illinois

  • - Aurora

Trial Details

FieldValue
Enrollment Target 203 participants
Start Date 2013-02-06
Est. Completion 2014-12-03
Phase Phase 2

Sponsor

Daiichi Sankyo

236 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01802775

The ClinicalTrials.gov registry entry for NCT01802775 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 203 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,204-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (95% lower). The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Peripheral Arterial Disease appearing as the primary indexed condition, and to 3 interventions - of which Aspirin is the first listed.

NCT01802775 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Florida, Michigan.

Frequently Asked Questions

What is clinical trial NCT01802775 about?

NCT01802775 is a clinical study titled "Edoxaban in Peripheral Arterial Disease". This study is a randomized, open-label, blinded endpoint, parallel-group, active-control, multi-center, proof-of-concept study in subjects with Peripheral Arterial Disease (PAD), designed to assess the safety and potential efficacy of adding edoxaban to aspirin following femoropopliteal endovascular...

What is the current status of trial NCT01802775?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 203 participants. The study started on 2013-02-06. Estimated completion is 2014-12-03.

What conditions does trial NCT01802775 study?

This clinical trial studies the following conditions: Peripheral Arterial Disease.

What interventions are being tested in trial NCT01802775?

The interventions under investigation include: Aspirin (DRUG), Clopidogrel (DRUG), edoxaban (DRUG).

Who is sponsoring clinical trial NCT01802775?

This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01802775 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Peripheral Arterial Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Peripheral Arterial Disease

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.